Clinical Trial Detail

NCT ID NCT03884972
Title Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

CLL/SLL

Therapies

Trabectedin + Venetoclax

Age Groups: senior adult

No variant requirements are available.